Commonwealth of Pennsylvania Public School Empls Retrmt SYS Reduces Position in Bristol-Myers Squibb Company (BMY)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lowered its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 122,394 shares of the biopharmaceutical company’s stock after selling 1,686 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Bristol-Myers Squibb were worth $6,820,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Baltimore Capital Management Inc. acquired a new stake in Bristol-Myers Squibb in the first quarter worth about $1,291,000. Aspen Investment Management Inc lifted its holdings in Bristol-Myers Squibb by 0.4% in the first quarter. Aspen Investment Management Inc now owns 12,551 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 50 shares during the period. Clean Yield Group acquired a new stake in Bristol-Myers Squibb in the first quarter worth about $256,000. Ray Gerald L & Associates Ltd. lifted its holdings in Bristol-Myers Squibb by 5.2% in the first quarter. Ray Gerald L & Associates Ltd. now owns 169,125 shares of the biopharmaceutical company’s stock worth $9,197,000 after purchasing an additional 8,340 shares during the period. Finally, Xact Kapitalforvaltning AB lifted its holdings in Bristol-Myers Squibb by 4.4% in the first quarter. Xact Kapitalforvaltning AB now owns 277,115 shares of the biopharmaceutical company’s stock worth $15,070,000 after purchasing an additional 11,732 shares during the period. Institutional investors and hedge funds own 69.82% of the company’s stock.

Several equities research analysts recently weighed in on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price objective for the company. in a report on Tuesday, August 22nd. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. Finally, Cowen set a $65.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $64.93.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.23% of the stock is currently owned by insiders.

Bristol-Myers Squibb Company (BMY) traded down $1.05 during midday trading on Wednesday, reaching $60.97. The company’s stock had a trading volume of 4,758,697 shares, compared to its average volume of 8,437,080. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The firm has a market cap of $99,860.00, a P/E ratio of 21.10, a PEG ratio of 2.37 and a beta of 1.17. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.77 EPS. research analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Commonwealth of Pennsylvania Public School Empls Retrmt SYS Reduces Position in Bristol-Myers Squibb Company (BMY)” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://ledgergazette.com/2017/12/07/commonwealth-of-pennsylvania-public-school-empls-retrmt-sys-sells-1686-shares-of-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply